Código QR

Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort

Background and aims. Patients with Myasthenia gravis (MG) are considered vulnerable as they may present with respiratory muscle weakness and because they are on immunosuppressive treatment; thereby, COVID-19 may have a detrimental effect on these patients. Vaccines against COVID-19 are currently ava...

Descrición completa

Gardado en:
Principais autores: Antonino Lupica, Vincenzo Di Stefano, Salvatore Iacono, Antonia Pignolo, Martina Quartana, Andrea Gagliardo, Brigida Fierro, Filippo Brighina
Formato: Artigo
Idioma:Inglês
Publicado: MDPI AG 2022-04-01
Series:Neurology International
Assuntos:
COVID-19
SARS-CoV2
vaccine
Myasthenia gravis
neuromuscular
myasthenic crisis
Acceso en liña:https://www.mdpi.com/2035-8377/14/2/33
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares